A triple combination of treatments on moderate COVID-19
A triple combination of interferon (IFN) α-2b, lopinavir tablets, and umifenovir was used to treat COVID-19 patients. It is important to explore whether the benefit of this therapy is time dependent.
Guardado en:
Autores principales: | Bao ChunMiao, Li BinBin, Zhou YuFeng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e6b38afe68524efaa9227a695bd93682 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
COVID-19 cases with delayed absorption of lung lesion
por: Li BinBin, et al.
Publicado: (2021) -
COVID-19 pandemic and management on hospital length of stay: A review
por: Fatemeh Abdollahi, et al.
Publicado: (2021) -
Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study
por: Rouamba T, et al.
Publicado: (2021) -
Prolonged rectal shedding of SARS-CoV-2 in a 22-day-old-neonate: a case report
por: Julie Niemann Holm-Jacobsen, et al.
Publicado: (2021) -
Viral Haplotypes in COVID-19 Patients Associated With Prolonged Viral Shedding
por: Yingping Wu, et al.
Publicado: (2021)